白细胞介素3受体α亚基与急性髓系白血病的靶向治疗

摘要

目前的化疗方案可能已达到治疗急性髓细胞白血病(AML)的极限,今后急性髓系白血病治疗的探索方向更多地是转向靶向治疗.单克隆抗体治疗已经在复发AML中产生明显的缓解率.在AML越来越多的异常分子描述中,白细胞介素3受体(IL-3R)α值得高度关注.IL-3R是造血生长因子受体家族成员之一,其α亚基CD123是白血病干细胞的特异标志,在白血病的发生和白血病细胞增殖、分化及凋亡中发挥重要作用.绝大部分急性髓系白血病高表达IL-3Rα.针对IL-3Rα靶向治疗的Ⅰ期临床研究已显示出一定的疗效.%At present,available chemotherapy has probably reached the limits of its potential in treating acute myeloid leukemia( AML ). Future exploration in the treating of AML will be more focused on targeting therapy. Monoclonal antibody therapy has received significant remission rate in relapsed AML. Among a growing number of abnormal molecular description, interleukin-3 receptor( IL-3R )ais calling for much attention. IL-3R is one of the hematopoietic growth factor receptor family members,and it's a subunit,CD123 ,is a specific marker of leukemic stem cells( Leukemic stem cell,LSC ),playing an important role in the development of leukemia and in the proliferation, differentiation and apoptosis of the leukemic cells. Numerous studies showed that most of acute myeloid leukemia highly express IL-3Ra. Phase I clinical study in therapy targeting IL-3Ra has already received some efficacy.